Sulaco, think about this. GILD could likely duplicate that feat today with cash flow. It is edging toward oncology to protect longevity problems that are perceived with its HIV and HCV franchises.---What better way to enhance all 3 endeavors than to own PPHM outright, with Bavi and its combo anti-tumor and anti-viral effects properly timed and dosed.Others here, including SL, have commented on the possibility of Bavi enhancing current and future SOCs.
There is some question why GILD recently paid Knight $225 million for its PRV that it had received on approval of therapy for a rare, neglected tropical disease---that PRV entitles the owner priority review before the FDA. What will GILD use that very expensive PRV for?
BTW, I have held GILD since 1996. I have far more than the 7-8 bagger you mention. I might have more than a passing interest in seeing a GILD-PPHM combination. We have one h___ of a lot more shares of PPHM than I do of the 1000s of shares of GILD in the portfolio. I might have to email CEO John Martin with the suggestion. OTOH, he probably has already thought of the notion.
News 
Market Data 
Discover 
AI
